<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03156842</url>
  </required_header>
  <id_info>
    <org_study_id>BR-FARC-CT-301</org_study_id>
    <nct_id>NCT03156842</nct_id>
  </id_info>
  <brief_title>Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia</brief_title>
  <acronym>FIRST</acronym>
  <official_title>A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia Who Fail to Respond Adequately to Fimasartan Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical study is to evaluate the efficacy and safety by comparing the
      fimasartan/amlodipine/rosuvastatin treatment group to the fimasartan/amlodipine treatment
      group and the fimasartan/rosuvastatin treatment group respectively at Week 8 in patients with
      essential hypertension and dyslipidemia who fail to respond to the fimasartan monotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 29, 2017</start_date>
  <completion_date type="Anticipated">May 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LDL-C</measure>
    <time_frame>8weeks from Baseline Visit</time_frame>
    <description>The percent change in LDL-C from baseline in the test group at Week 8 compared to the fimasartan 60 mg/amlodipine 10 mg combination treatment group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sitting systolic blood pressure(SiSBP)</measure>
    <time_frame>8weeks from Baseline Visit</time_frame>
    <description>The change in Sitting systolic blood pressure(SiSBP) from baseline in the test group at Week 8 compared to the fimasartan 60 mg and rosuvastatin 20 mg concomitant treatment group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sitting systolic blood pressure(SiSBP)</measure>
    <time_frame>8weeks from Baseline Visit</time_frame>
    <description>The change in Sitting systolic blood pressure(SiSBP) from baseline in the test group at Week 8 compared to the fimasartan 60 mg/amlodipine 10 mg combination treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-C</measure>
    <time_frame>8weeks from Baseline Visit</time_frame>
    <description>The percent change in LDL-C from baseline in the test group at Week 8 compared to the fimasartan 60 mg and rosuvastatin 20 mg concomitant treatment group</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Essential Hypertension</condition>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Fimasartan/Amlodipine, Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Co-administration of a fixed dose combination of Fimasartan/Amlodipine and Rosuvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fimasartan/Amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a fixed dose combination of Fimasartan/Amlodipine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fimasartan, Rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Co-administration of Fimasartan and Rosuvastatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan/Amlodipine, Rosuvastatin</intervention_name>
    <description>&quot;A fixed dose combination tablet of Fimasartan and Amlodipine&quot; and &quot;Rosuvastatin&quot; will be administrated once daily on treatment period.</description>
    <arm_group_label>Fimasartan/Amlodipine, Rosuvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan/Amlodipine</intervention_name>
    <description>&quot;A fixed dose combination tablet of Fimasartan and Amlodipine&quot; will be administrated once daily on treatment period.</description>
    <arm_group_label>Fimasartan/Amlodipine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan, Rosuvastatin</intervention_name>
    <description>&quot;Fimasartan&quot; and &quot;Rosuvastatin&quot; will be administrated once daily on treatment period.</description>
    <arm_group_label>Fimasartan, Rosuvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Voluntarily provided a written consent to participate in this clinical study

          2. Male or female adults aged 19-70 years

          3. Patients must have been confirmed essential hypertension and dyslipidemia at Screening
             visit (V1)

          4. Uncontrolled blood pressure (140 mmHg ≤ mean Sitting systolic blood pressure(SiSBP) &lt;
             180 mmHg) at the baseline visit (V3) after the fimasartan 60 mg monotherapy

          5. Subjects who meet the following criteria of fasting serum lipid levels confirmed at
             the baseline visit (V3) after undergoing the therapeutic lifestyle change (TLC)

          6. Treatment compliance of fimasartan 60 mg ≥70% at the baseline visit (V3)

          7. Able to understand this study, be cooperative in the execution of the study, and
             participate in the study until its completion

        Exclusion Criteria:

          1. Severe hypertension with mean Sitting systolic blood pressure(SiSBP) ≥180 mmHg or
             Sitting diastolic blood pressure(SiDBP) ≥110 mmHg at the screening visit (V1) and the
             baseline visit (V2, or orthostatic hypotension accompanied by symptoms

          2. Differences between arms greater than 20 mmHg for Sitting systolic blood
             pressure(SiSBP) and 10 mmHg for Sitting diastolic blood pressure(SiDBP) are present on
             3 consecutive readings at the screening visit (V1)

          3. Secondary hypertension patients: Secondary hypertension is not limited to the
             following diseases; (e.g., renovascular disease, adrenal medullary and cortical
             hyperfunctions, coarctation of the aorta, hyperaldosteronism, unilateral or bilateral
             renal artery stenosis, Cushing's syndrome, pheochromocytoma, and polycystic kidney
             disease)

          4. Uncontrolled diabetes mellitus (currently on insulin, or HbA1c &gt;9% at the pre-baseline
             visit (V2)), or uncontrolled hypothyroidism (TSH ≥1.5 times the upper limit of normal
             at the pre-baseline visit (V2))

          5. Heart disease (heart failure of New York Heart Association (NYHA) class 3 and 4), or
             ischemic heart disease (angina pectoris, myocardial infarction), peripheral vascular
             disease, percutaneous transluminal coronary angioplasty, or coronary artery bypass
             graft, etc. within 6 months prior to the screening visit (V1)

          6. Clinically significant ventricular tachycardia, atrial fibrillation, atrial flutter;
             or other arrhythmia conditions that are determined to be clinically significant by the
             investigator

          7. Hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease,
             aortic stenosis, or hemodynamically significant aortic valve stenosis or mitral valve
             stenosis

          8. Cerebrovascular disorder (stroke, cerebral infarction, transient cerebral ischemic
             attack, cerebral hemorrhage, etc. within 6 months prior to the screening visit (V1)

          9. Pregnant or lactating women

         10. Planning pregnancy during the study period or have childbearing potential but are not
             using acceptable contraceptive methods (Contraceptive methods: Refer to Section 10.1
             in this document.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eun-Seok Jeon</last_name>
    <phone>82-2-3410-3448</phone>
    <email>eunseok.jeon@samsung.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2017</study_first_submitted>
  <study_first_submitted_qc>May 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2017</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Fimasartan</keyword>
  <keyword>Rosuvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

